Quick Answer
Cartesian Therapeutics, Inc. reported Revenue From Contract With Customer Excluding Assessed Tax of $400.0 thousand for the year ending 2025.
- Cartesian Therapeutics, Inc. showed a decrease of -99.0% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from Cartesian Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 10 years of available data (2016 to 2025), Cartesian Therapeutics, Inc.'s Revenue From Contract With Customer Excluding Assessed Tax has declined by 95.1%.
- Historical annual values: Fiscal year 2025: $400.0 thousand | Fiscal year 2024: $38.28 million | Fiscal year 2023: $26.00 million | Fiscal year 2022: $110.78 million | Fiscal year 2021: $85.08 million | Fiscal year 2020: $16.60 million | Fiscal year 2019: $6.68 million | Fiscal year 2018: $903.0 thousand | Fiscal year 2017: $207.0 thousand | Fiscal year 2016: $8.08 million.
- Data sourced from SEC EDGAR public filings as of June 24, 2026.
Last verified: